Sign in Sign up for free

Last updated: 11 June 2024 at 4:15pm EST

Alison Lawton Net Worth




The estimated Net Worth of Alison Frances Lawton is at least $91.2 Thousand dollars as of 11 November 2014. Ms. Lawton owns over 2,500 units of Verastem Inc stock worth over $7,000 and over the last 12 years she sold VSTM stock worth over $0. In addition, she makes $84,157 as Independent Director at Verastem Inc.

Ms. Lawton VSTM stock SEC Form 4 insiders trading

Alison has made over 1 trades of the Verastem Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she bought 2,500 units of VSTM stock worth $22,925 on 11 November 2014.

The largest trade she's ever made was buying 2,500 units of Verastem Inc stock on 11 November 2014 worth over $22,925. On average, Alison trades about 100 units every 0 days since 2012. As of 11 November 2014 she still owns at least 2,500 units of Verastem Inc stock.

You can see the complete history of Ms. Lawton stock trades at the bottom of the page.





Alison Lawton biography

Lawton Alison Frances is an Independent Director of the Company. Ms. Lawton has been the Chief Executive Officer, President and Director of Kaleido Biosciences, Inc. (Kaleido) since 2018. She previously served as President and Chief Operating Officer of Kaleido, beginning in December 2017. Ms. Lawton was Chief Operating Officer at Aura Biosciences, Inc. from 2015 to 2017. Ms. Lawton also served as Chief Operating Officer at OvaScience Inc., a life sciences company, from January 2013 to January 2014. In addition, from 2014 to 2017, Ms. Lawton served as a biotech consultant for various companies, including as Chief Operating Officer consultant at X4 Pharmaceuticals. Ms. Lawton worked at various positions of increasing responsibility at Genzyme Corporation (Genzyme) and subsequently at Sanofi-Aventis, following its 2011 acquisition of Genzyme, each a global biopharmaceutical company. Ms. Lawton served as head of Genzyme Biosurgery, where she was responsible for Genzyme’s global orthopedics, surgical and cell therapy and regenerative medicine businesses. Prior to that, Ms. Lawton oversaw Global Market Access at Genzyme, which included Regulatory Affairs, Global Health Outcomes and Strategic Pricing, Global Public Policy and Global Product Safety & Risk Management. Before joining Genzyme, Ms. Lawton worked for seven years in the United Kingdom at Parke-Davis, a pharmaceutical company. Ms. Lawton serves on the board of directors of ProQR Therapeutics, a public biopharmaceutical company. She also has served on the boards of directors of CoLucid Pharmaceuticals, Inc. until its acquisition by Eli Lilly & Co. and of Cubist Pharmaceuticals until its acquisition by Merck & Co., Inc. She is past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for the Cell and Gene Therapy Committee. She earned her B.Sc. in Pharmacology, with honors, from King’s College London.

What is the salary of Alison Lawton?

As the Independent Director of Verastem Inc, the total compensation of Alison Lawton at Verastem Inc is $84,157. There are 10 executives at Verastem Inc getting paid more, with Brian Stuglik having the highest compensation of $1,917,190.



How old is Alison Lawton?

Alison Lawton is 58, she's been the Independent Director of Verastem Inc since 2013. There are 8 older and 7 younger executives at Verastem Inc. The oldest executive at Verastem Inc is Timothy Barberich, 72, who is the Independent Director.

What's Alison Lawton's mailing address?

Alison's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134.

Insiders trading at Verastem Inc

Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal, and Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.



What does Verastem Inc do?

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com



What does Verastem Inc's logo look like?

Verastem Inc logo

Complete history of Ms. Lawton stock trades at Aeglea BioTherapeutics Inc, Verastem Inc, Magenta Therapeutics Inc, Kaleido Biosciences Inc, and X4 Pharmaceuticals

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
11 Nov 2014 VSTM Verastem Inc Alison Frances Lawton
Director
 Buy 2,500 $9.17 $22,925
11 Nov 2014
2,500 ↗


Verastem Inc executives and stock owners

Verastem Inc executives and other stock owners filed with the SEC include: